Debiopharm Group
Debiopharm Group, a Swiss-based biopharmaceutical company, is headquartered in Lausanne, Switzerland (CH). Founded in 1971, Debiopharm has established itself as a leader in the development of innovative therapies for oncology and infectious diseases. The company focuses on drug development, with a strong emphasis on precision medicine and advanced therapeutic solutions. With a robust pipeline of products, Debiopharm is renowned for its unique approach to drug formulation and delivery, particularly in the field of oncology. The company has achieved significant milestones, including successful partnerships and collaborations that enhance its market position. Debiopharm's commitment to improving patient outcomes through cutting-edge research and development solidifies its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Debiopharm Group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Debiopharm Group's score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Debiopharm Group's reported carbon emissions
Debiopharm Group, headquartered in Switzerland (CH), currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established specific reduction targets or initiatives related to climate commitments. As of now, Debiopharm Group does not inherit emissions data from any parent or related organizations, indicating that their climate strategy is independent. Without specific emissions data or reduction initiatives, it is unclear how the company plans to address its carbon footprint or contribute to climate action within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Debiopharm Group is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
